APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma

Keisuke Kosumi, Yoshifumi Baba, Takatsugu Ishimoto, Kazuto Harada, Kenichi Nakamura, Mayuko Ohuchi, Yuki Kiyozumi, Daisuke Izumi, Ryuma Tokunaga, Katsunobu Taki, Takaaki Higashi, Tatsunori Miyata, Hironobu Shigaki, Junji Kurashige, Yukiharu Hiyoshi, Masaaki Iwatsuki, Shiro Iwagami, Yasuo Sakamoto, Yuji Miyamoto, Naoya Yoshida & 3 others Eiji Oki, Masayuki Watanabe, Hideo Baba

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

APOBEC3B belongs to the cytidine deaminase apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC3) family of enzymes and induces C to T transitions of target DNA by cytidine deamination. Recently, several mutations in various cancers have been linked to APOBEC3B, suggesting a crucial role for this protein in carcinogenesis and cancer development. However, the significance of APOBEC3B in esophageal squamous cell carcinoma (ESCC) remains uncertain. In addition, the APOBEC3B immunoreactivity in cancer tissues is uncertain. Recently, we have demonstrated that PIK3CA mutation and the methylation level of long interspersed nucleotide element 1 (LINE-1) (a surrogate marker of global DNA methylation level) are prognostic markers and have crucial role on malignancy in ESCC patients. This study aims to clarify the impact of APOBEC3B on the clinical, pathological, and molecular features of ESCC. We evaluated APOBEC3B expression in ESCC and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathological features, and the molecular features of ESCC (PIK3CA mutation, p53 expression, and LINE-1 methylation level). The immunoreactivity and mRNA level of APOBEC3B were significantly higher in cancer tissues than in noncancerous esophageal mucosae (P = 0.050). APOBEC3B expression was significantly correlated with PIK3CA mutation (P = 0.013), particularly with C to T transitions of PIK3CA (P = 0.041). Moreover, a high expression of APOBEC3B was significantly associated with LINE-1 hypomethylation (P = 0.027). Given the crucial roles of PIK3CA mutation and LINE-1 methylation levels, our findings might provide new insights into the biological mechanisms of ESCC tumorigenesis and progression.

Original languageEnglish
Article number26
Pages (from-to)1-9
Number of pages9
JournalMedical Oncology
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Long Interspersed Nucleotide Elements
Mutation
Methylation
Neoplasms
Carcinogenesis
Cytidine Deaminase
Cytidine
Deamination
DNA Methylation
Esophageal Squamous Cell Carcinoma
Biomarkers
Messenger RNA
DNA
Enzymes
Proteins

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Kosumi, K., Baba, Y., Ishimoto, T., Harada, K., Nakamura, K., Ohuchi, M., ... Baba, H. (2016). APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. Medical Oncology, 33(3), 1-9. [26]. https://doi.org/10.1007/s12032-016-0739-7

APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. / Kosumi, Keisuke; Baba, Yoshifumi; Ishimoto, Takatsugu; Harada, Kazuto; Nakamura, Kenichi; Ohuchi, Mayuko; Kiyozumi, Yuki; Izumi, Daisuke; Tokunaga, Ryuma; Taki, Katsunobu; Higashi, Takaaki; Miyata, Tatsunori; Shigaki, Hironobu; Kurashige, Junji; Hiyoshi, Yukiharu; Iwatsuki, Masaaki; Iwagami, Shiro; Sakamoto, Yasuo; Miyamoto, Yuji; Yoshida, Naoya; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo.

In: Medical Oncology, Vol. 33, No. 3, 26, 01.03.2016, p. 1-9.

Research output: Contribution to journalArticle

Kosumi, K, Baba, Y, Ishimoto, T, Harada, K, Nakamura, K, Ohuchi, M, Kiyozumi, Y, Izumi, D, Tokunaga, R, Taki, K, Higashi, T, Miyata, T, Shigaki, H, Kurashige, J, Hiyoshi, Y, Iwatsuki, M, Iwagami, S, Sakamoto, Y, Miyamoto, Y, Yoshida, N, Oki, E, Watanabe, M & Baba, H 2016, 'APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma', Medical Oncology, vol. 33, no. 3, 26, pp. 1-9. https://doi.org/10.1007/s12032-016-0739-7
Kosumi, Keisuke ; Baba, Yoshifumi ; Ishimoto, Takatsugu ; Harada, Kazuto ; Nakamura, Kenichi ; Ohuchi, Mayuko ; Kiyozumi, Yuki ; Izumi, Daisuke ; Tokunaga, Ryuma ; Taki, Katsunobu ; Higashi, Takaaki ; Miyata, Tatsunori ; Shigaki, Hironobu ; Kurashige, Junji ; Hiyoshi, Yukiharu ; Iwatsuki, Masaaki ; Iwagami, Shiro ; Sakamoto, Yasuo ; Miyamoto, Yuji ; Yoshida, Naoya ; Oki, Eiji ; Watanabe, Masayuki ; Baba, Hideo. / APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma. In: Medical Oncology. 2016 ; Vol. 33, No. 3. pp. 1-9.
@article{9952b3997fe9484bb2bd26a6b12d4a11,
title = "APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma",
abstract = "APOBEC3B belongs to the cytidine deaminase apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC3) family of enzymes and induces C to T transitions of target DNA by cytidine deamination. Recently, several mutations in various cancers have been linked to APOBEC3B, suggesting a crucial role for this protein in carcinogenesis and cancer development. However, the significance of APOBEC3B in esophageal squamous cell carcinoma (ESCC) remains uncertain. In addition, the APOBEC3B immunoreactivity in cancer tissues is uncertain. Recently, we have demonstrated that PIK3CA mutation and the methylation level of long interspersed nucleotide element 1 (LINE-1) (a surrogate marker of global DNA methylation level) are prognostic markers and have crucial role on malignancy in ESCC patients. This study aims to clarify the impact of APOBEC3B on the clinical, pathological, and molecular features of ESCC. We evaluated APOBEC3B expression in ESCC and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathological features, and the molecular features of ESCC (PIK3CA mutation, p53 expression, and LINE-1 methylation level). The immunoreactivity and mRNA level of APOBEC3B were significantly higher in cancer tissues than in noncancerous esophageal mucosae (P = 0.050). APOBEC3B expression was significantly correlated with PIK3CA mutation (P = 0.013), particularly with C to T transitions of PIK3CA (P = 0.041). Moreover, a high expression of APOBEC3B was significantly associated with LINE-1 hypomethylation (P = 0.027). Given the crucial roles of PIK3CA mutation and LINE-1 methylation levels, our findings might provide new insights into the biological mechanisms of ESCC tumorigenesis and progression.",
author = "Keisuke Kosumi and Yoshifumi Baba and Takatsugu Ishimoto and Kazuto Harada and Kenichi Nakamura and Mayuko Ohuchi and Yuki Kiyozumi and Daisuke Izumi and Ryuma Tokunaga and Katsunobu Taki and Takaaki Higashi and Tatsunori Miyata and Hironobu Shigaki and Junji Kurashige and Yukiharu Hiyoshi and Masaaki Iwatsuki and Shiro Iwagami and Yasuo Sakamoto and Yuji Miyamoto and Naoya Yoshida and Eiji Oki and Masayuki Watanabe and Hideo Baba",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s12032-016-0739-7",
language = "English",
volume = "33",
pages = "1--9",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - APOBEC3B is an enzymatic source of molecular alterations in esophageal squamous cell carcinoma

AU - Kosumi, Keisuke

AU - Baba, Yoshifumi

AU - Ishimoto, Takatsugu

AU - Harada, Kazuto

AU - Nakamura, Kenichi

AU - Ohuchi, Mayuko

AU - Kiyozumi, Yuki

AU - Izumi, Daisuke

AU - Tokunaga, Ryuma

AU - Taki, Katsunobu

AU - Higashi, Takaaki

AU - Miyata, Tatsunori

AU - Shigaki, Hironobu

AU - Kurashige, Junji

AU - Hiyoshi, Yukiharu

AU - Iwatsuki, Masaaki

AU - Iwagami, Shiro

AU - Sakamoto, Yasuo

AU - Miyamoto, Yuji

AU - Yoshida, Naoya

AU - Oki, Eiji

AU - Watanabe, Masayuki

AU - Baba, Hideo

PY - 2016/3/1

Y1 - 2016/3/1

N2 - APOBEC3B belongs to the cytidine deaminase apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC3) family of enzymes and induces C to T transitions of target DNA by cytidine deamination. Recently, several mutations in various cancers have been linked to APOBEC3B, suggesting a crucial role for this protein in carcinogenesis and cancer development. However, the significance of APOBEC3B in esophageal squamous cell carcinoma (ESCC) remains uncertain. In addition, the APOBEC3B immunoreactivity in cancer tissues is uncertain. Recently, we have demonstrated that PIK3CA mutation and the methylation level of long interspersed nucleotide element 1 (LINE-1) (a surrogate marker of global DNA methylation level) are prognostic markers and have crucial role on malignancy in ESCC patients. This study aims to clarify the impact of APOBEC3B on the clinical, pathological, and molecular features of ESCC. We evaluated APOBEC3B expression in ESCC and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathological features, and the molecular features of ESCC (PIK3CA mutation, p53 expression, and LINE-1 methylation level). The immunoreactivity and mRNA level of APOBEC3B were significantly higher in cancer tissues than in noncancerous esophageal mucosae (P = 0.050). APOBEC3B expression was significantly correlated with PIK3CA mutation (P = 0.013), particularly with C to T transitions of PIK3CA (P = 0.041). Moreover, a high expression of APOBEC3B was significantly associated with LINE-1 hypomethylation (P = 0.027). Given the crucial roles of PIK3CA mutation and LINE-1 methylation levels, our findings might provide new insights into the biological mechanisms of ESCC tumorigenesis and progression.

AB - APOBEC3B belongs to the cytidine deaminase apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC3) family of enzymes and induces C to T transitions of target DNA by cytidine deamination. Recently, several mutations in various cancers have been linked to APOBEC3B, suggesting a crucial role for this protein in carcinogenesis and cancer development. However, the significance of APOBEC3B in esophageal squamous cell carcinoma (ESCC) remains uncertain. In addition, the APOBEC3B immunoreactivity in cancer tissues is uncertain. Recently, we have demonstrated that PIK3CA mutation and the methylation level of long interspersed nucleotide element 1 (LINE-1) (a surrogate marker of global DNA methylation level) are prognostic markers and have crucial role on malignancy in ESCC patients. This study aims to clarify the impact of APOBEC3B on the clinical, pathological, and molecular features of ESCC. We evaluated APOBEC3B expression in ESCC and investigated the relationships among the immunoreactivity of APOBEC3B, clinical and pathological features, and the molecular features of ESCC (PIK3CA mutation, p53 expression, and LINE-1 methylation level). The immunoreactivity and mRNA level of APOBEC3B were significantly higher in cancer tissues than in noncancerous esophageal mucosae (P = 0.050). APOBEC3B expression was significantly correlated with PIK3CA mutation (P = 0.013), particularly with C to T transitions of PIK3CA (P = 0.041). Moreover, a high expression of APOBEC3B was significantly associated with LINE-1 hypomethylation (P = 0.027). Given the crucial roles of PIK3CA mutation and LINE-1 methylation levels, our findings might provide new insights into the biological mechanisms of ESCC tumorigenesis and progression.

UR - http://www.scopus.com/inward/record.url?scp=84958244891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958244891&partnerID=8YFLogxK

U2 - 10.1007/s12032-016-0739-7

DO - 10.1007/s12032-016-0739-7

M3 - Article

VL - 33

SP - 1

EP - 9

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

M1 - 26

ER -